How should I manage a 59-year-old man with hypertension (on losartan and amlodipine), chronic hepatitis B infection, decompensated cirrhosis presenting with massive tense ascites, bilateral lower‑extremity edema and dyspnea, after therapeutic paracentesis of 3 L of sanguineous fluid, who has anemia, thrombocytopenia, hypoalbuminemia, mild coagulopathy, elevated transaminases, acute kidney injury, and low ascitic fluid white‑cell count (making spontaneous bacterial peritonitis unlikely)?

Management of Decompensated Cirrhosis with Acute Kidney Injury Post-Paracentesis

This patient requires immediate intravenous albumin administration (18-24 g for the 3 L removed), aggressive management of acute kidney injury with albumin and vasoconstrictors, initiation of diuretics once stabilized, antiviral therapy for hepatitis B, and urgent liver transplant evaluation. 1

Immediate Post-Paracentesis Management

Albumin Replacement - Critical Priority

Your patient had 3 L of ascites removed but likely did not receive adequate albumin replacement. The 2025 AGA guidelines mandate albumin administration when renal insufficiency or electrolyte abnormalities are present, even for volumes <5 L 1. Given his creatinine doubled from 114 to 244 µmol/L (1.3 to 2.8 mg/dL), this represents post-paracentesis circulatory dysfunction.

• Administer 6-8 g of 20-25% IV albumin per liter removed = 18-24 g total immediately 1
• This should have been given at the time of paracentesis but give it now

Acute Kidney Injury Management

His eGFR dropped to ~26 mL/min with BUN:Cr ratio of 9.45, indicating hepatorenal physiology rather than prerenal azotemia (ratio would be >20 if prerenal). This patient meets criteria for hepatorenal syndrome-acute kidney injury (HRS-AKI) given:

• Cirrhosis with ascites
• Creatinine increase >0.3 mg/dL within 48 hours or ≥50% from baseline
• No response to volume expansion (implied by continued rise)
• No nephrotoxic drugs evident
• No structural kidney disease (ultrasound shows normal-sized kidneys)

Treatment algorithm for HRS-AKI:

1. Continue albumin 20-40 g/day IV 2, 3
2. Add vasoconstrictor therapy - terlipressin is now FDA-approved and first-line 4, 3
   • Alternative: norepinephrine if terlipressin unavailable
   • Midodrine + octreotide as third-line option
3. Monitor creatinine every 2-3 days for response (target: decrease to <1.5× baseline)

Diuretic Management

Hold diuretics temporarily until creatinine stabilizes. His current medications (losartan and amlodipine) are problematic:

Critical Medication Changes

• Discontinue losartan immediately 5 - ARBs are contraindicated in decompensated cirrhosis with AKI and worsen renal function through efferent arteriolar vasodilation
• Discontinue amlodipine - peripheral vasodilators worsen the hyperdynamic circulation in cirrhosis
• These antihypertensives are appropriate for compensated cirrhosis but harmful in decompensation

Once Creatinine Stabilizes (target <150 µmol/L):

Initiate diuretics in 100:40 ratio 1:

• Spironolactone 100 mg once daily (morning dosing to avoid nocturia)
• Furosemide 40 mg once daily
• Target weight loss: 0.5 kg/day (he has peripheral edema, so could tolerate 1 kg/day)
• Monitor electrolytes and creatinine every 3-7 days initially

Common pitfall: Starting diuretics too aggressively in the setting of AKI will worsen renal function. Wait for stabilization.

Sodium and Fluid Management

• Sodium restriction to 2000 mg (90 mmol) daily 1
• Dietitian referral mandatory 1
• No fluid restriction needed - his sodium is 135.66 mmol/L (low-normal but >125), so fluid restriction only indicated if sodium drops to ≤125 mmol/L 6

Hepatitis B Management

His HBsAg is reactive with evidence of hepatic decompensation (albumin 24.78 g/L, elevated bilirubin, prolonged PT). Antiviral therapy is mandatory and urgent:

• Start tenofovir alafenamide (TAF) 25 mg daily or tenofovir disoproxil fumarate (TDF) 7
• TAF preferred in decompensated cirrhosis due to better renal and bone safety profile
• Check HBV DNA, HBeAg status if not already done
• Recent data shows both TAF and tenofovir amibufenamide achieve >85% complete virological response at 48 weeks in HBV-related decompensated cirrhosis 7

Ascites Characterization and Infection Surveillance

His ascitic fluid analysis shows:

• WBC 34 cells/µL with 60% PMNs = ~20 PMN/µL (well below 250/µL threshold for SBP) 1
• No antibiotics needed currently - PMN count does not meet SBP criteria
• Sanguineous fluid suggests either traumatic tap or possible malignancy

Critical next step: Calculate SAAG (serum albumin - ascitic albumin) 1:

• Need ascitic fluid albumin level (not provided)
• SAAG ≥1.1 g/dL confirms portal hypertension
• If SAAG <1.1 g/dL, consider peritoneal carcinomatosis (especially given sanguineous fluid)

Given sanguineous ascites, order:

• Ascitic fluid cytology to rule out hepatocellular carcinoma with peritoneal spread
• AFP (alpha-fetoprotein) level
• Triphasic liver CT or MRI with contrast to evaluate for HCC

Liver Transplant Evaluation - Urgent Priority

This patient requires immediate transplant evaluation regardless of MELD score 1, 8. His decompensation features include:

• Grade 3 (massive) ascites requiring large-volume paracentesis
• Hepatorenal syndrome-AKI
• Severe hypoalbuminemia (24.78 g/L)
• Coagulopathy (INR 1.27, PT activity 59.9%)

The 2025 AGA guidelines explicitly state: "All patients with ascites and/or hepatic hydrothorax should be considered for liver transplantation evaluation, regardless of their MELD score" 1. Recent evidence shows ~40% mortality reduction with transplant even in low-MELD patients with decompensation 8.

His calculated MELD-Na is approximately 16-18 (based on creatinine 2.8, bilirubin 1.5, INR 1.27, sodium 136), but clinical decompensation trumps MELD score for transplant consideration.

Monitoring Plan

Daily while hospitalized:

• Weight, intake/output
• Blood pressure (expect low-normal in cirrhosis; 90-100 systolic acceptable)
• Clinical assessment for encephalopathy

Every 2-3 days:

• Creatinine, BUN, electrolytes (sodium, potassium)
• Albumin level
• INR if on diuretics

Weekly:

• Liver function tests (AST, ALT, bilirubin, albumin)
• CBC (monitor thrombocytopenia - currently 95×10⁹/L)

Refractory Ascites Planning

If ascites recurs rapidly despite maximum diuretics (spironolactone 400 mg + furosemide 160 mg daily), he has refractory ascites 1:

Management options in order:

1. Serial therapeutic paracentesis (every 2-4 weeks as needed) with albumin replacement
2. TIPS (transjugular intrahepatic portosystemic shunt) evaluation 1 - appropriate if:
   • Child-Pugh score ≤12
   • Bilirubin <3-5 mg/dL
   • No hepatic encephalopathy
   • Creatinine <2 mg/dL (after stabilization)
3. If not TIPS candidate: continue serial paracentesis or consider palliative care discussion

Key Pitfalls to Avoid

1. Do not continue ARBs/ACE inhibitors in decompensated cirrhosis - they worsen HRS 5
2. Do not start diuretics during active AKI - wait for creatinine stabilization
3. Do not restrict fluids unless sodium ≤125 mmol/L 6
4. Do not delay transplant evaluation - mortality is high even with low MELD 8
5. Do not forget albumin replacement post-paracentesis - prevents circulatory dysfunction 1
6. Do not use NSAIDs - will precipitate further renal injury 5

Prognosis Discussion

With massive ascites, HRS-AKI, and hypoalbuminemia, his 1-year mortality without transplant is approximately 50-70%. Liver transplantation is the only definitive treatment 8. Bridge therapies (albumin, vasoconstrictors, TIPS if eligible) aim to stabilize him for transplant.